Keros Therapeutics (NASDAQ:KROS) Price Target Cut to $41.00 by Analysts at Scotiabank

Keros Therapeutics (NASDAQ:KROS) had its target price cut by Scotiabank from $44.00 to $41.00 in a report published on Thursday,Benzinga reports. They currently have a sector outperform rating on the stock.

A number of other analysts have also recently weighed in on KROS. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. TD Cowen downgraded Keros Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Jefferies Financial Group assumed coverage on Keros Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating on the stock. BTIG Research cut Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, December 12th. Finally, Truist Financial lowered their price objective on shares of Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating for the company in a research report on Monday, December 23rd. Five investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $52.56.

Keros Therapeutics Price Performance

NASDAQ KROS opened at $10.86 on Thursday. Keros Therapeutics has a 1-year low of $9.77 and a 1-year high of $73.00. The firm has a market capitalization of $439.94 million, a P/E ratio of -2.08 and a beta of 1.43. The business’s 50-day simple moving average is $36.37 and its 200-day simple moving average is $47.13.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business had revenue of $0.39 million during the quarter. During the same quarter last year, the firm earned ($1.33) EPS. The business’s revenue for the quarter was up 4750.0% compared to the same quarter last year. On average, equities research analysts expect that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Hedge Funds Weigh In On Keros Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. FMR LLC raised its holdings in Keros Therapeutics by 3.8% in the third quarter. FMR LLC now owns 4,899,134 shares of the company’s stock valued at $284,493,000 after acquiring an additional 179,374 shares in the last quarter. Alkeon Capital Management LLC lifted its position in shares of Keros Therapeutics by 18.7% during the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock worth $110,194,000 after purchasing an additional 298,694 shares during the last quarter. Darwin Global Management Ltd. grew its stake in Keros Therapeutics by 6.3% in the second quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company’s stock worth $68,772,000 after purchasing an additional 89,952 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after buying an additional 577,220 shares during the last quarter. Finally, Holocene Advisors LP raised its stake in Keros Therapeutics by 22.5% during the third quarter. Holocene Advisors LP now owns 843,110 shares of the company’s stock valued at $48,959,000 after buying an additional 154,784 shares in the last quarter. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.